Advertisement

Current Colorectal Cancer Reports

, Volume 11, Issue 6, pp 298–302 | Cite as

FIRE-3 and C80405: Is There a Best Choice for Initial Treatment of Metastatic Colorectal Cancer?

  • Jan Van den BrandeEmail author
  • Kostas Papadimitriou
  • Marika Rasschaert
  • Marc Peeters
Adjuvant Therapy for Colon Cancers (AB Benson III and A de Gramont, Section Editors)
  • 163 Downloads
Part of the following topical collections:
  1. Topical Collection on Adjuvant Therapy for Colon Cancers

Abstract

In the treatment of metastatic colorectal cancer, chemotherapy is used as a backbone to which an angiogenesis inhibitor such as bevacizumab (vascular endothelial growth factor [VEGF]) or a monoclonal antibody to the epidermal growth factor receptor (EGFR) such as cetuximab or panitumumab is added. In this article, we seek answers to the question: “FIRE-3 and C80405: is there a best choice for initial treatment of metastatic colorectal cancer?” In the absence of clear and univocal evidence that EGFR inhibitors should be used in the first-line setting for patients with metastatic RAS wild-type colorectal cancer, the physician and patient still have the choice between bevacizumab or an EGFR inhibitor as addition to the chemotherapy (FOLFIRI or FOLFOX) in this setting. This choice will be influenced by the different toxicity profiles of bevacizumab and cetuximab or panitumumab and will therefore depend on existing comorbidities of the patient and patient/physician preferences. The higher response rate of the combination of chemotherapy with cetuximab could make this treatment more interesting as induction therapy.

Keywords

Metastatic colorectal cancer Cetuximab Bevacizumab FOLFIRI FOLFOX KRAS RAS Exon 2 Panitumumab 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Jan Van den Brande, Kostas Papadimitriou, Marika Rasschaert and Marc Peeters declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMedGoogle Scholar
  2. 2.
    Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–7.CrossRefGoogle Scholar
  3. 3.••
    Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–75. In this phase 3 trial the authors demonstrate a statistically significant overall survival advantage in favour of chemotherapy + cetuximab.CrossRefPubMedGoogle Scholar
  4. 4.••
    Venook AP, Donna N, Heinz-Josef L, et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Abstract Number: LBA3. J Clin Oncol. 2014;32:5s. In this phase 3 trial the authors demonstrate that either chemotherapy + bevacizumab or chemotherapy + cetuximab is appropriate in first line.CrossRefGoogle Scholar
  5. 5.
    Lenz H, Niedzwiecki D, Innocenti F, et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC). Ann Oncol. 2014;25:1–41.CrossRefGoogle Scholar
  6. 6.
    Stintzing S, Modest DP, von Fischer Weikersthal L, et al. Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306) in the final RAS evaluable population. Ann Oncol. 2014;25:1–41.CrossRefGoogle Scholar
  7. 7.
    Fakih MG. Metastatic colorectal cancer: current state and future directions. J Clin Oncol. 2015.Google Scholar
  8. 8.•
    Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32(21):2240–7. This randomized phase II study was the first to show a survival advantage in the treatment arm with chemotherapy + panitumumab, in comparison with chemotherapy + bevacizumab.CrossRefPubMedGoogle Scholar
  9. 9.
    Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–34.CrossRefPubMedGoogle Scholar
  10. 10.
    Loupakis F, Cremolini C, Salvatore L, et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer. 2014;50(1):57–63.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Jan Van den Brande
    • 1
    Email author
  • Kostas Papadimitriou
    • 1
  • Marika Rasschaert
    • 1
  • Marc Peeters
    • 1
  1. 1.Department of Medical OncologyAntwerp University HospitalEdegemBelgium

Personalised recommendations